WebMar 16, 2024 · The FDA decision was based on positive data from this Boehringer Ingelheim-funded Phase 3 trial, in which 663 participants with progressive ILDs were treated with Ofev (150 mg twice daily) or given a placebo.. Results showed that Ofev treatment significantly slowed the decline in lung function, as measured by forced vital capacity — the average … WebOct 10, 2024 · In September 2024, Ofev was approved in the U.S. as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic …
ConnectDI
WebMay 25, 2024 · The INBUILD ® trial, which was published in the New England Journal of Medicine, was a randomized, double-blind, placebo-controlled, parallel group trial conducted at 153 sites in 15 countries that evaluated the efficacy and safety of OFEV ® (150 mg, twice-daily) over 52 weeks in patients with chronic fibrosing ILDs with a progressive ... Web6 Nicht-Vitamin K-antagonistische orale Antikoagulantien (NOAKs): Real-World-Studien–Update und Arzneimittelinteraktionen solidware hock
References - Clinical Review Report: Nintedanib (Ofev)
WebBoehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacturing and marketing of innovative health care products. Back … WebMar 4, 2024 · OFEV ®, a multi-targeted tyrosine kinase inhibitor that inhibits key pathways involved in lung fibrosis in ILDs, [10] is also indicated for the treatment of idiopathic pulmonary fibrosis (IPF), and to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD (SSc-ILD) – two types of ILDs. [11] WebNov 11, 2024 · Ofev recently received breakthrough therapy designation from the FDA as a potential treatment for progressive fibrosing ILD. A new analysis of the INBUILD data now … solid washing up bar